louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00350506: A Trial Evaluating the Clinical Applicability, Correlation, and Modeling of Cardiac CT Using 64 Detector Row VCT
Official title: An Open-label, Non-randomized, Multi-center Trial Evaluating the Clinical Applicability, Correlation, and Modeling of Cardiac CT Using 64 Detector Row VCT
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Coronary Artery Disease
Lead sponsor: GE Healthcare
Sponsor class: INDUSTRY
First posted: 2006-07-10
Enrollment: 77
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: To compare computed tomography (CT) images (pictures) of the coronary arteries using the General Electric (GE) LightSpeed VCT scanner with x-ray coronary angiography in patients referred for an x-ray coronary angiography.


Eligibility criteria: Inclusion Criteria:

* Patients scheduled for elective diagnostic catheterization OR
* Elective diagnostic catheterization has been performed within the past 2 weeks but no less than 24 hours prior to the coronary CTA procedure with no intervention performed or change of the patient clinical status.
* Age ≥18 years but ≤75 years.

Exclusion Criteria:

* Prior coronary stent implantation
* Prior coronary artery bypass grafting or other heart surgery
* Prior pacemaker or internal defibrillator lead implantation
* Prior artificial heart valve
* Biochemical renal insufficiency (CrSerum \> 1.6) or on dialysis
* Resting HR \> 100 at the time of enrollment
* Contraindication to β-blockade or calcium channel blocker

  * NYHA-IV
  * High-grade atrioventricular (AV) block
  * Systolic blood pressure \<90 mm Hg
  * Severe asthma or active bronchospasm and/or chronic obstructive pulmonary disease
* Atrial fibrillation
* Inability to provide informed consent
* Evidence of ongoing or active clinical instability

  * Acute chest pain (sudden onset)
  * Acute myocardial infarction
  * Cardiac shock
  * Acute pulmonary edema

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Princeton
country: United States
facility: GE Healthcare
state: New Jersey
Study officials:
affiliation: GE Healthcare
name: Robert Centofanti, MS
role: STUDY_DIRECTOR
References:
Clinical trial NCT05897606: Effect of Multi Vitamin and Mineral Supplementation of Liver Enzymes and Sonography in Patient With NAFLD
Official title: Effect of Multi Vitamin and Mineral Supplementation of Liver Enzymes and Sonography in Patient With Non-alcoholic Fatty Disease (NAFLD); RCR
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Non-Alcoholic Fatty Liver Disease
Lead sponsor: Sulaimany Polytechnic university
Sponsor class: OTHER
First posted: 2023-06-09
Enrollment: 160
Sex: ALL
Minimum age (years): 22
Maximum age (years): 78
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Intervention group received multivitamin and minerral
Primary purpose: TREATMENT

Brief summary: The study was performed on 160 participants, to ensure the impact of multi vitamin and mineral to reduce NAFLD

Detailed description: This study was performed on 160 participants, to ensure the impact of multi vitamin and mineral to reduce NAFLD.

Participants were randomly selected to participate in the study. Then divided into the groups (intervention and placebo). Intervention received supplementation for 12 weeks and placebo received same capsule was made for placebo groups.

Eligibility criteria: Inclusion Criteria:

* Participants with NAFLD diagnosed

Exclusion Criteria:

* subjects who in the last 6 months received vitamin or mineral supplementation, those with chronic conditions such as diabetes, hypertension, and heart disease, unwillingness to continue the study protocol, lactating women and pregnant women.

Primary outcomes:
measure: Multivitamin and minerals supplementation has role in reduce liver enzymes
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Kurdistan
country: Iraq
facility: Hawal Fateh
state: Kalar
Study officials:
affiliation: Nursing Department, Kalar Technical College, Sulaimani polytechnic university, Sulaimani, Iraq
name: HAWAL F Lateef, Msc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00115206: Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy
Official title: A Pilot Study of the Effects of Neutropenia on Patient Reported Outcomes During Chemotherapy With or Without Neulasta® (Pegfilgrastim) in Subjects With Advanced NSCLC
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Non-Small Cell Lung Cancer
Keywords: Non Small Cell Lung Cancer
NSCLC
Fever
Neutropenia
Neulasta®
Quality of Life
Chemotherapy
Amgen
Lead sponsor: Amgen
Sponsor class: INDUSTRY
First posted: 2005-06-22
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to estimate the relationship between patient reported outcomes (PROs) and neutropenia (or its complications) in NSCLC subjects receiving chemotherapy with or without Neulasta® (pegfilgrastim).


Eligibility criteria: Inclusion Criteria: - Non-small cell lung cancer, not previously treated with chemotherapy or radiotherapy - ECOG performance status 0 or 1 - ANC greater than or equal to 2.0 x 10\^9/L Exclusion Criteria: - Cancer other than NSCLC within 5 years of enrollment, with the exception of surgically cured basal cell carcinoma or in situ carcinoma of the cervix - Treatment less than or equal to 30 days prior with any experimental agent - Subjects with symptomatic brain metastases - Subject is currently enrolled or has not yet completed at least 30 days since ending other investigational device or drug trial(s) or is receiving other investigational agent(s)

Primary outcomes:
measure: Quality of Life
Secondary outcomes:
measure: Quality of Life, *Neutropenia, *Hospitalization, *Disease Response
Other outcomes:
Locations:
Study officials:
affiliation: Amgen
name: MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01521806: Effects of Dietary Fiber on Insulin Sensitivity
Official title: Effects of Dieatry Fiber on Insulin Sensitivity in Pre- and Post-menopausal Women
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Focus of the Study is Insulin Sensitivity
Keywords: insulin sensitivity
resistant starch
Lead sponsor: Ingredion Incorporated
Sponsor class: INDUSTRY
First posted: 2012-01-31
Enrollment: 40
Sex: FEMALE
Minimum age (years): 19
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: This study will examine the effects of a dietary fiber on insulin sensitivity in overweight and obese women. The fiber will be added to snack foods and women will consume the foods for four weeks. In one four-week period, 15 g of fiber will be added, and 30 g will added in another period. In a third period, no fiber will be added to the snack foods. Insulin senstivity will be measured at the end of each treatment period.


Eligibility criteria: Inclusion Criteria:

* Impaired fasting glucose
* Overweight and obese

Exclusion Criteria:

* Diabetes, Presence of chronic diseases

Primary outcomes:
measure: Insulin sensitivity
timeFrame: 5-hr test, performed 3 times within a 20-week period
Secondary outcomes:
measure: Mitocondrial function
timeFrame: 3 times, with a 20-week period
measure: Meal tolerance test
timeFrame: 3 times, within a 20-week period
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: Clinical Research Unit
state: Alabama
Study officials:
affiliation: University of Alabama at Birmingham
name: Barbara Gower, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02955706: Assessment the Efficacy of Acetyl-L-carnitine in Patient With Alzheimer's Disease
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy of Acetyl-L-carnitine in Patient With Alzheimer's Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Alzheimer Disease
Lead sponsor: Dong-A ST Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2016-11-04
Enrollment: 265
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: clinical trial to assess the efficacy of Acetyl-L-carnitine

Detailed description: A multicenter, randomized, double-blind, placebo-controlled clinical trial to assess the efficacy of Acetyl-L-carnitine in patient with Alzheimer's disease

Eligibility criteria: Inclusion Criteria:

* More than 50 Years
* probable Alzheimer disease according to DSM-IV and NINCDS-ADRDA standard
* 12≤K-MMSE(screening)≤26
* be able to perform examinations
* Patient taking donepezil(5mg or 10mg/day) more than 3 months
* be able to visit to hospital with caregiver

Exclusion Criteria:

* possible or probable or definite vascular dementia according to NINDS-AIREN standard
* CNS disease(Cerebrovascular diseases, Epilepsy etc) to cause dementia
* Illiteracy
* Patient taking galantamine, memantine, rivastigmine within three months
* Patient taking brain enhancer, thyroid hormone within 4 weeks
* Patient taking Central nervous system stimulant, Antipsychotic agent, anticholinergic agent within 2 weeks
* at screenig blood test: AST, ALT≥ 3 X upper limit of normal range or Hb≤8g/dL or platelet\<100,000/mm3 or Serum creatinine ≥ 3 X upper limit of normal range
* Abnormal result of Vit.B12, Syphilis serology, TSH
* Severe Depression, Schizophrenia, Alcoholism, Drug addiction
* Parkinson's disease (need to drug therapy)
* Angina, Myocardial infarction, ischemia within six months
* Head injury with sense of loss within six months
* Patient taking other IP within three months
* Hypersensitivity to IP
* Sever Hearing problems or Visual impairment

Primary outcomes:
measure: ADAS-cog
timeFrame: 24week
Secondary outcomes:
measure: K-MMSE
timeFrame: 12week, 24week
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Konkuk university medical center
Study officials:
affiliation: Konkuk University Medical Center
name: Seol Hee Han, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01280006: Effect of Selective and Nonselective Cyclooxygenase Enzyme Inhibition on Arterial Blood Pressure and Cerebral Blood Flow With Exposure to Intermittent Hypoxia in Humans
Official title: Effect of Selective and Nonselective Cyclooxygenase Enzyme Inhibition on Arterial Blood Pressure and Cerebral Blood Flow With Exposure to Intermittent Hypoxia in Humans
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Obstructive Sleep Apnea
Hypertension
Cardiovascular Diseases
Stroke
Keywords: Obstructive Sleep Apnea
Hypoxia
Sleep
Blood Pressure
Hypertension
Myocardial Infarction
Stroke
Ventilation
Brain
Cerebral Blood Flow
Renal Blood Flow
Lead sponsor: University of Calgary
Sponsor class: OTHER
First posted: 2011-01-20
Enrollment: 12
Sex: MALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The study has been designed to assess the effect of cyclooxygenase inhibition on blood pressure, cerebral blood flow, ventilation and renal hemodynamics following chronic intermittent hypoxia exposure.

Detailed description: The study will specifically evaluate:

1. Cardiovascular effect of cyclooxygenase inhibitors on cerebral, vascular, blood pressure and homeostatic responses following chronic intermittent hypoxia exposure.
2. Ventilatory response of cyclooxygenase inhibitors following chronic intermittent hypoxia exposure
3. Evaluate the renal hemodynamic effect of chronic intermittent hypoxia exposure and cyclooxygenase inhibition.

Eligibility criteria: Inclusion Criteria:

* Healthy male subjects
* 18 - 45 years of age
* Informed written consent

Exclusion Criteria:

* Any history of cardio-respiratory diseases, ongoing medication, smoking, trauma, acute illnesses, collagen vascular diseases, rheumatoid arthritis, osteoarthritis

Primary outcomes:
measure: Arterial Blood Pressure
timeFrame: Six weeks
measure: Cerebral Blood Flow
timeFrame: Six weeks
Secondary outcomes:
measure: Ventilatory Response
timeFrame: Six weeks.
measure: Renal Hemodynamics
timeFrame: Six weeks
Other outcomes:
Locations:
city: Calgary
country: Canada
facility: The Laboratory of Human Cerebrovascular Physiology, HMRB 209 & HMRB 230, University of Calgary
state: Alberta
Study officials:
affiliation: University of Calgary
name: Marc J Poulin, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Beaudin AE, Pun M, Yang C, Nicholl DD, Steinback CD, Slater DM, Wynne-Edwards KE, Hanly PJ, Ahmed SB, Poulin MJ. Cyclooxygenases 1 and 2 differentially regulate blood pressure and cerebrovascular responses to acute and chronic intermittent hypoxia: implications for sleep apnea. J Am Heart Assoc. 2014 May 9;3(3):e000875. doi: 10.1161/JAHA.114.000875.
Clinical trial NCT06794099: Study on the Applicability of CCR Criteria in Rectal Cancer
Official title: Applicability of CCR Assessment Criteria in PMMR Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy Combined with Immunotherapy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: PMMR/MSS Adenocarcinoma of the Colon or Rectum
Neoadjuvant Chemoradiotherapy
Immunotherapy
Complete Response
Lead sponsor: Peking University Cancer Hospital & Institute
Sponsor class: OTHER
First posted: 2025-01-27
Enrollment: 177
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This retrospective study evaluated medical records, endoscopic findings, and MRI images of rectal cancer patients who underwent neoadjuvant chemoradiotherapy (with or without immunotherapy) followed by surgery at Peking University Cancer Hospital between January 2019 and October 2024.

Brief summary: This study aims to explore how well the usual ways of checking if rectal cancer patients are free of disease signs after treatment work for a new treatment method. The new method combines chemotherapy, radiation, and immune-boosting drugs before surgery. We know these usual ways work for the standard treatment, but we're not sure if they're good enough for this new combo treatment. We'll look at patients with a specific type of rectal cancer that doesn't respond well to just immune-boosting drugs alone. By comparing how patients treated with the new method and the old method respond, we hope to find better ways to tell if the treatment is really working, which could help improve treatment plans for these patients.


Eligibility criteria: Inclusion Criteria:

1. histopathologically confirmed adenocarcinoma;
2. pMMR/MSS tumors;
3. clinical staging of T3-T4 or any lymph node-positive T (N+);
4. no evidence of distant metastasis based on radiological examinations;
5. treatment with long-course chemoradiotherapy (LCRT) with or without immune checkpoint inhibitors (ICI);
6. post-neoadjuvant therapy evaluation with endoscopy and pelvic MRI.

Exclusion Criteria:

1. Presence of other active malignancies;
2. Having severe comorbidities, such as heart failure, severe hepatic or renal insufficiency, etc;
3. Lack of imaging and endoscopic examinations;
4. Treatment plan does not meet the study requirements.

Primary outcomes:
measure: sensitivity, specificity, accuracy, and AUC
timeFrame: January 2025
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University Cancer Hospital & Institute
state: Beijing
Study officials:
References:
Clinical trial NCT01257399: Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase
Official title: Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Ulcerative Colitis in Remission
Lead sponsor: Tillotts Pharma AG
Sponsor class: INDUSTRY
Collaborators: name: Zeria Pharmaceutical
First posted: 2010-12-09
Enrollment: 251
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To demonstrate that import Mesalazine (ASACOL®) is non-inferior to the reference drug, marketed Mesalazine, regarding the primary endpoint (rate of non-emergence of bloody stool), in patients with Ulcerative Colitis in remission, treated for 48 weeks.


Eligibility criteria: Inclusion Criteria:

* Patients with ulcerative colitis in remission who are defined to show an Ulcerative Colitis-Disease Activity Index (UC-DAI) score of 2 or less and a bloody stool score of 0.

Exclusion Criteria:

* Patients who take adrenal corticosteroid (oral formulation, enemas, suppository, agents for hemorrhoidal disease, injectable solution) within 14 days before start of administration of clinical study drug.

Primary outcomes:
measure: Rate of non-emergence of bloody stool
timeFrame: Week 48
Secondary outcomes:
measure: 1) Period of non-emergence of bloody stool, 2) Rate of non-recurrence, 3) Period of non-recurrence, 4) Reduction of UC-DAI score
timeFrame: Week 48
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai Hospital
Study officials:
References:
citation: Sun J, Yuan Y. Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Remission Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study. Adv Ther. 2016 Mar;33(3):410-22. doi: 10.1007/s12325-016-0304-y. Epub 2016 Feb 23.
Clinical trial NCT04630899: Comparison of Passive and Active Joint Mobilization for Chronic Ankle Instability
Official title: Comparison of Passive and Active Joint Mobilization for Chronic Ankle Instability: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Musculoskeletal Manipulations
Chronic Instability of Joint
Ankle Joint
Lead sponsor: Sahmyook University
Sponsor class: OTHER
First posted: 2020-11-16
Enrollment: 30
Sex: ALL
Minimum age (years): 19
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The features of CAI were confirmed through studies that 64% to 77% had extra-articular conditions mainly related to calf tendon disorder. In addition, joints are laxity, sensory motors are deficient, and the range of dorsi flexion is decreased. this study is to investigate the effects of active joint mobilization(AJM) under weight-bearing conditions to stimulate various proprioceptors for CAI with deficiency in sensorimotor and postural control.


Eligibility criteria: Inclusion Criteria:

* First ankle sprain one year before clinical trial
* A score of less than 24 on the Cumberland Ankle Instability Tool (CAIT)
* No ankle sprains occurred within 4 weeks of starting the test
* Two or more more ankle sprains in the past month

Exclusion Criteria:

* If you have a history of lower extremity surgery
* In case of receiving treatment for the affected ankle within 1 month
* If you have a psychological problem

Primary outcomes:
measure: Ankle instability
timeFrame: 4 weeks
measure: Range of motion
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Gwangju
country: Korea, Republic of
facility: Gwangju Health University
Study officials:
References:
Clinical trial NCT05024799: Effect of Different Sedation and Analgesia Strategies on Patients With Mechanical Ventilation
Official title: Effect of Different Sedation and Analgesia Strategies on Patients With Mechanical Ventilation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Respiratory Insufficiency
Lead sponsor: The Affiliated Hospital of Qingdao University
Sponsor class: OTHER
First posted: 2021-08-27
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Most patients in ICU are treated with a combination of analgesics and sedatives in most cases. Due to the different mechanism of different sedative and analgesic drugs, different antagonistic or synergistic effects may occur when combined with drugs, resulting in different clinical effects, especially significant effects on ventilators for patients with assisted breathing. Therefore, this study hopes to compare the effects of different sedative and analgesic drug combinations on the duration of mechanical ventilation for patients with ventilators, so as to guide the clinical adoption of a more reasonable sedative and analgesic scheme.


Eligibility criteria: Inclusion Criteria:

* Adults who are treated with sedation and analgesia for invasive mechanical ventilation

Exclusion Criteria:

* they have baseline severe cognitive impairment; were pregnant or breast-feeding; were blind, deaf ; had second-degree or third-degree heart block or bradycardia requiring intervention; had an allergy to the experimental drugs; had an indication for benzodiazepines; were anticipated to have immediate discontinuation of mechanical ventilation; were expected to have neuromuscular blockade for more than 48 hours; were in a moribund state; or had received mechanical ventilation for more than 96 hours before meeting all inclusion criteria.

Primary outcomes:
measure: ventilator-free days at 28 days
timeFrame: at 28 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: